GH Research (NASDAQ:GHRS) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of GH Research (NASDAQ:GHRS) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports. Cantor Fitzgerald also issued estimates for GH Research’s FY2025 earnings at ($0.84) EPS.

GHRS has been the subject of a number of other research reports. Stifel Nicolaus lifted their price objective on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Guggenheim reduced their price target on shares of GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Royal Bank of Canada initiated coverage on shares of GH Research in a report on Friday, March 7th. They issued an “outperform” rating and a $31.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Friday, May 9th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, GH Research has an average rating of “Buy” and an average target price of $30.43.

GH Research Trading Up 7.2%

NASDAQ GHRS opened at $10.70 on Tuesday. GH Research has a 1-year low of $6.00 and a 1-year high of $20.50. The stock has a 50-day moving average of $10.27 and a 200-day moving average of $9.90. The firm has a market cap of $556.70 million, a PE ratio of -13.54 and a beta of 0.86.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.42. As a group, equities research analysts forecast that GH Research will post -0.8 earnings per share for the current fiscal year.

Institutional Trading of GH Research

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. increased its stake in GH Research by 3.9% in the first quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company’s stock worth $76,599,000 after purchasing an additional 257,959 shares during the period. Lynx1 Capital Management LP boosted its holdings in GH Research by 15.8% in the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after acquiring an additional 663,100 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of GH Research during the first quarter worth about $8,272,000. Troluce Capital Advisors LLC acquired a new stake in shares of GH Research during the first quarter worth about $1,716,000. Finally, Diadema Partners LP acquired a new position in GH Research in the fourth quarter valued at approximately $711,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).